Investing in The Next China

Activist Insight

China Cord Blood ditches management buyout

Heng Ren to Testify Before Congressional Committee on January 26.

Bloomberg: Sinovac Investor Demands 75% More for China Vaccine Maker Buyout

Seeking Alpha: Investor Says Sinovac Insiders' Bid 75% Undervalued

Bio Portfolio: Insiders Need to Raise Bid by 75%, Remove Poison Pill - Heng Ren Investments

Yahoo Finance: Heng Ren's Letter to Sinovac Challenges Bid Valuation

Morningstar: Heng Ren Challenges Low Bid by Sinovac Insiders

ChinaBio Today: Heng Ren's Action Regarding Sinovac Biotech and SAIF Partners Featured Deal

China Money NetworK: Investor Challenges SAIF-Backed Deal for Sinovac

Street Insider: Sinovac Biotech's "Epic Failure of Corporate Governance" Casts Doubt on Business Ethics of Children's Vaccine Maker

Mergermarket: Sinovac activist goes public with price hike demands; going-private proposal an 'epic failure of corporate governance'

Mergermarket: Sinovac activist to go public with price hike demands

Mergermarket: Activist Profile of Heng Ren Investments LP

Heng Ren Investments Profile in 21st Century Business Herald, China's Largest Financial Publication

Barron's: Heng Ren's Prescription for Turnaround for China Nepstar Chain Drugstore

[12  >>